Expanded Hemodialysis Therapy Market size was valued at USD 83.92 Billion in 2023 and is anticipated to reach USD 156.3 Billion by the end of 2036, registering around 4.9% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of expanded hemodialysis therapy is assessed at USD 87.62 Billion. The major factor for market growth is the rising cases of chronic kidney diseases among the global population. As the failure of kidneys halts the process of cleaning blood and waste outflow, it requires the external help of advanced medical devices for filtering the blood. Thus, the rising chronic kidney diseases around the world are anticipated to bring in lucrative growth opportunities for market expansion during the forecast period. As per the estimations, about 11% of the world’s population was suffering from chronic kidney disease in 2022.
With the rising shift of people towards a sedentary lifestyle, there has been a significant increase in lifestyle disorders such as diabetes and hypertension. Escalation in such diseases leads to blood disorders which in turn is estimated to create a positive outlook for market growth during the analysis period. Along with that, the rising technological advancement in the field of healthcare and medicine is attributed to propel the development of novel medical products and is expected to aid the development of the global expanded hemodialysis therapy market in the upcoming years. Also, the rising cases of chronic diseases and acute disorders coupled with the rising prevalence of rare diseases is anticipated to drive market growth in the upcoming years. In addition to other factors, the increasing cases of end-stage renal disease (ESRD) and other kidney-related diseases are expected to increase the demand for dialysis and expanded hemodialysis therapy to maintain proper kidney functioning which in turn is projected to expand the market size during the forecast period.
Growth Drivers
Growing Cases of End-Stage Kidney Disease (ESKD) – The prevalence of end-stage kidney disease (ESKD) is growing on the account of the rapid escalation of unhealthy lifestyles and the adoption of destructive food items which are packaged and processed. This trend is anticipated to decrease the functioning capacity of the kidney which generates the need for expanded hemodialysis therapy for the treatment process. Hence, the rising cases of end-stage kidney disease (ESKD) among the global population are anticipated to bring positive opportunities for market growth during the forecast period. The National Institute of Diabetes and Digestive and Kidney Diseases stated that nearly 786,000 people in the United States were living with end-stage kidney disease in 2020, out of which almost 71% were on dialysis and 29% with a kidney transplant.
Increased in Lifestyle Disorders – In the recent period, the rate of lifestyle disorders such as diabetes and hypertension has grown considerably owing to poor diet, sedentary lifestyle, reduced physical activity, high consumption of alcohol, and others. People diagnosed with such diseases are considered to be more prone to develop a kidney disorder. Thus, failure of kidneys owing to lifestyle diseases is estimated to increase the utilization rate of expanded hemodialysis therapy and subsequently expand the market size. As per the data shared by the World Health Organization (WHO), it has been estimated that diabetes was responsible for 1.5 million deaths which are equivalent to 48% of all death across the globe in 2019. On the other hand, WHO also stated that the number of people living with hypertension across the globe has doubled to 1.28 in the last thirty years.
Burgeoning Geriatric Population in the World – Elderly people have a higher risk of kidney failure owing to a greater chance of being affected by diseases and weakened immunity along with deteriorating body organs. This results in proper dialysis for enhancing the survival rates which is projected to impetus the use of expanded hemodialysis therapy in the upcoming years. As per the estimations, the number of old people across the world is expected to double by 2050 and reach 2 billion up from 1.5 billion in 2030.
Constant Support from the Government to Treat Chronic Kidney Disease – The government of different nations are focusing on building better healthcare facilities and providing enhanced healthcare policies for various diseases, including chronic kidney disease. This factor is attributed to bringing in lucrative growth opportunities for market growth during the assessment period. For instance, the Centers for Medicare & Medicaid Services (CMS) declared the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model to provide quality care by reducing chronic kidney disease expenditure for patients. This ETC model is estimated to boost the economy by saving around USD 23 million in five and a half years.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.9% |
|
Base Year Market Size (2023) |
USD 83.92 Billion |
|
Forecast Year Market Size (2036) |
USD 156.3 Billion |
|
Regional Scope |
|
Type (Short Daily, Conventional Long-Term, Nocturnal)
The global expanded hemodialysis therapy market is segmented and analyzed for demand and supply by type into short daily, conventional long-term, and nocturnal. Out of the three types of hemodialysis, the conventional segment is estimated to gain the largest market share of about 42% in the year 2036. The major factor attributed to the growth of the segment is the rising cases of kidney disorders that require dialysis on a regular basis. Also, the rising number of deaths owing to untreated kidney disease is estimated to fuel segment growth. Recent statistics published in 2023 revealed that approximately 1 million people die across the globe owing to untreated kidney failure each year. Also, the various advantages of conventional hemodialysis therapy such as high effectiveness, better results, positive outcomes, and enhanced patient experience are also expected to aid the expand the segment size during the forecast period.
End-user (Hospital, Independent Dialysis, Home Dialysis)
The global expanded hemodialysis therapy market is also segmented and analyzed for demand and supply by end-user into hospital, independent dialysis, and home dialysis. Amongst these three segments, the hospital segment is expected to garner a significant share of around 46% in the year 2036 with a notable CAGR value. The major factors attributed to the growing segment size are the rising number of hospitals across the world and the presence of hospitals in every region coupled with rising investments by the government and key players for enhancing the hospital infrastructure. For instance, there were over 8,000 hospitals in Japan as of 2020. Korea, by contrast, had about 4,000 hospitals. In addition, there were more than 6000 hospitals in the United States. Furthermore, the rising preference of the global population to get treated in effective hospital settings and the availability of advanced medical devices and trained medical professionals to perform dialysis, and expanded hemodialysis therapy are also estimated to drive segment growth during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Type |
|
|
By Application |
|
|
By End-user |
|
North American Market Forecast
The North American expanded hemodialysis therapy market, amongst the market in all the other regions, is projected to hold the largest market share of about 35% by the end of 2036. The growth of the market can be attributed majorly to the rising healthcare expenditure, growing disposable income, and rising demand for the development of new products. All these factors are expected to propel the adoption rate of expanded hemodialysis therapy in the upcoming years. The national health expenditure of the U.S. in 2020, rose by 9.7% and reached USD 4.1 trillion, or USD 12,350 for every person, as per the CMS. Further, the availability of a strong healthcare network in the region, coupled with the availability of supportive policies by the governing bodies that promote the market players to opt for investing in more research works to bring up more feasible solutions so as to develop efficient expanded hemodialysis therapy options are also anticipated to contribute to market growth in the region.
APAC Market Statistics
The Asia Pacific expanded hemodialysis therapy market, amongst the market in all the other regions, is projected to hold the second largest share of about 28% during the forecast period. Rapid growth in the geriatric population who are more prone to kidney disorders along with the rising prevalence of chronic diseases among the people living in the Asia Pacific region is considered to be a major factor for market growth during the analysis period. Furthermore, the constant support by the regulatory bodies and major key players in the region is also considered to positively contribute to market growth in the region in the next few years. Also, the presence of major key players along with the availability of effective diagnostic imaging services for diagnosing underlying kidney problems in the region is estimated to projected to create a positive outlook for market growth during the forecast period.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. One of the main factors that are attributed to propel the growth of the market is the availability of a large pool of patients in the region with chronic kidney disease, kidney stones, and other kidney-related disorders which needs to be treated with expanded hemodialysis therapy. In addition to the aforementioned factor, also the rapid rise of awareness about kidney disease and its treatment is anticipated to increase the opportunities for the utilization of expanded hemodialysis therapy.
B. Braun Melsungen AG has finally acquired Intermedt Medizin & Technik GmbH which is allowing the company to complete its extensive portfolio as a systems provider for extracorporeal blood treatment (dialysis).
Asahi Kasei Corporation has obtained the approval for manufacturing and selling Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg in Japan for the treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?